ENTX vs. VIR
ENTX (Entera Bio Ltd) and VIR (Vir Biotechnology, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, ENTX returned -23.99%/yr vs -27.17%/yr for VIR. At a 0.13 correlation, their price movements are largely independent.
Performance
ENTX vs. VIR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ENTX achieves a -20.10% return, which is significantly lower than VIR's 68.49% return.
ENTX
- 1D
- 4.73%
- 1M
- 25.00%
- YTD
- -20.10%
- 6M
- -11.93%
- 1Y
- -20.92%
- 3Y*
- 23.26%
- 5Y*
- -23.99%
- 10Y*
- —
VIR
- 1D
- 6.17%
- 1M
- 10.55%
- YTD
- 68.49%
- 6M
- 69.62%
- 1Y
- 101.19%
- 3Y*
- -25.49%
- 5Y*
- -27.17%
- 10Y*
- —
ENTX vs. VIR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
ENTX Entera Bio Ltd | -20.10% | -8.49% | 253.33% | -17.81% | -74.07% | 160.65% | -49.53% | 7.54% |
VIR Vir Biotechnology, Inc. | 68.49% | -17.85% | -27.04% | -60.25% | -39.55% | 56.35% | 112.96% | -22.14% |
Correlation
The correlation between ENTX and VIR is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.25 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.19 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.17 |
Correlation (All Time) Calculated using the full available price history since Oct 11, 2019 | 0.13 |
The correlation between ENTX and VIR shifts across timeframes, from 0.13 (all time) to 0.25 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
ENTX:
$74.02M
VIR:
$1.50B
ENTX:
-$0.11
VIR:
-$3.14
ENTX:
6.93
VIR:
1.84
ENTX:
$0.00
VIR:
$65.50M
ENTX:
-$15.00K
VIR:
$183.11M
ENTX:
-$12.42M
VIR:
-$448.10M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ENTX vs. VIR — Risk / Return Rank
ENTX
VIR
ENTX vs. VIR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Entera Bio Ltd (ENTX) and Vir Biotechnology, Inc. (VIR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ENTX | VIR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.70 | ||
| Sortino ratioReturn per unit of downside risk | -2.09 | ||
| Omega ratioGain probability vs. loss probability | 1.03 | 1.27 | -0.24 |
| Calmar ratioReturn relative to maximum drawdown | -0.31 | 3.66 | -3.96 |
| Martin ratioReturn relative to average drawdown | -0.50 | 8.34 | -8.84 |
Loading charts...
Drawdowns
ENTX vs. VIR - Drawdown Comparison
The maximum ENTX drawdown since its inception was -93.15%, roughly equal to the maximum VIR drawdown of -94.85%. Use the drawdown chart below to compare losses from any high point for ENTX and VIR.
Loading charts...
Drawdown Indicators
| ENTX | VIR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.15% | -94.85% | +1.70% |
Max Drawdown (1Y)Largest decline over 1 year | -68.15% | -27.82% | -40.33% |
Max Drawdown (3Y)Largest decline over 3 years | -68.15% | -82.86% | +14.71% |
Max Drawdown (5Y)Largest decline over 5 years | -92.05% | -92.15% | +0.10% |
Current DrawdownCurrent decline from peak | -78.77% | -87.77% | +9.00% |
Average DrawdownAverage peak-to-trough decline | -68.15% | -67.82% | -0.33% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 42.00% | 12.18% | +29.82% |
Volatility
ENTX vs. VIR - Volatility Comparison
Entera Bio Ltd (ENTX) has a higher volatility of 26.30% compared to Vir Biotechnology, Inc. (VIR) at 16.76%. This indicates that ENTX's price experiences larger fluctuations and is considered to be riskier than VIR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ENTX | VIR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 26.30% | 16.76% | +9.54% |
Volatility (6M)Calculated over the trailing 6-month period | 72.34% | 48.81% | +23.53% |
Volatility (1Y)Calculated over the trailing 1-year period | 87.26% | 70.06% | +17.20% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 87.15% | 72.86% | +14.29% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 110.26% | 95.99% | +14.27% |
Dividends
ENTX vs. VIR - Dividend Comparison
Neither ENTX nor VIR has paid dividends to shareholders.
Financials
ENTX vs. VIR - Financials Comparison
This section allows you to compare key financial metrics between Entera Bio Ltd and Vir Biotechnology, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ENTX and VIR have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ENTX has higher volatility (26.30%) compared to VIR (16.76%). In terms of maximum drawdown, ENTX dropped -93.15% vs VIR's -94.85%.
VIR currently has the higher Sharpe Ratio (1.45 vs -0.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ENTX and VIR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer